SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Stockholders approved all four proposals at the 2026 Annual Meeting of Stockholders held on June 11, 2026: election of seven directors, advisory approval of named executive officer compensation, approval of the Third Amendment to the 2017 Equity Incentive Plan (increasing shares by 9,000,000), and ratification of Grant Thornton LLP as independent auditor.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Blackbaud's June 10, 2026 annual meeting, covering three proposals: advisory approval of named executive officer compensation, amendment and restatement of the 2016 Equity and Incentive Compensation Plan, and ratification of Ernst & Young LLP as independent auditor. The filing explicitly states the vote tallies for each proposal, which is the hallmark of Item 5.07 shareholder_vote_results disclosures.
View raw filing on EDGAR →Inogen held its 2026 Annual Meeting of Stockholders and disclosed complete voting results on five matters: election of Class III directors (Boehnlein and Sahney), ratification of Deloitte & Touche LLP as independent auditor, advisory vote on executive compensation, approval of the Amended and Restated 2023 Equity Incentive Plan with 750,000 additional shares, and a failed amendment to declassify the Board.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Green Plains Inc.'s 2026 annual shareholder meeting held on June 5, 2026. The filing details voting outcomes for four proposals: election of nine directors, approval of an amendment to the 2019 Equity Incentive Plan to increase authorized shares, ratification of KPMG LLP as independent auditors, and an advisory vote on executive compensation. All matters were approved. Shareholder vote results are material to investors as they reflect governance decisions and capital allocation approvals.
View raw filing on EDGAR →This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds totaling $30 million (two bonds: $15M at 4.625% due 12/28/2029 and $15M at 4.500% due 6/23/2031). While Item 2.03 typically signals covenant_breach or debt acceleration events, this filing describes routine debt issuance by a Federal Home Loan Bank in the capital markets—a core funding mechanism explicitly noted as "material to the Bank" but presented as ordinary business activity. The disclosure does not indicate a breach, acceleration, or triggering event; rather, it reports scheduled debt issuances. This does not fit cleanly into covenant_breach (no breach indicated) or the other specific event types, making other_material the most appropriate classification for a material debt issuance that falls outside the standard taxonomy.
View raw filing on EDGAR →This Item 2.03 disclosure describes the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Des Moines. While the filing explicitly states "consolidated obligations issuance is material to the Bank," the disclosure is primarily informational and regulatory in nature—explaining the structure, joint-and-several liability framework, and reporting methodology rather than announcing a specific new debt issuance event. The actual obligations are detailed in Schedule A (not provided here). This does not fit cleanly into covenant_breach (no violation alleged) or the more specific debt-related categories, making other_material the most appropriate classification.
View raw filing on EDGAR →This 8-K Item 2.03 discloses the issuance of consolidated obligations (debt securities) totaling approximately $775 million in principal across four separate issuances with trade dates of 06/08–06/09/2026. While Item 2.03 is technically designated for "Creation of a Direct Financial Obligation," the taxonomy does not include a specific "debt_issuance" category. The disclosure is material to investors as it represents significant new debt obligations, but it does not fit cleanly into covenant_breach (no breach alleged), dilutive_issuance (debt, not equity), or ma_activity (no acquisition or merger). The event is routine debt financing for a Federal Home Loan Bank, making other_material the most appropriate classification.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of Consolidated Bonds (debt securities) totaling approximately $92 million across six bond offerings with trade dates in June 2026. While Item 2.03 is technically designed for "creation of a direct financial obligation," the filing itself explicitly states "although Consolidated Obligations issuance is material to the FHLB, we have not made a judgment as to the materiality of any particular Consolidated Obligation or Obligations." The disclosure is routine debt issuance reporting rather than a discrete material event like a covenant breach or going-concern issue. This falls outside the more specific event categories and is best classified as other_material given the FHLB's own acknowledgment of materiality combined with the routine nature of the disclosure.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of consolidated obligations (debt securities) totaling approximately $195 million across six bond tranches with varying maturities (2027–2031) and coupon rates (4.02%–4.50%). While Item 2.03 typically signals covenant breaches or direct financial obligations under off-balance-sheet arrangements, this filing explicitly discloses routine debt issuance by a Federal Home Loan Bank in the ordinary course of business. The Bank notes that "consolidated obligations issuance is material to the Bank" but has not made materiality judgments on individual issuances. This is a material debt financing event, but it does not fit the specific taxonomy categories (covenant_breach implies default risk; ma_activity implies acquisition/disposition). The disclosure is material to investors assessing the Bank's capital structure and leverage, warranting classification as other_material rather than forcing it into an ill-fitting category.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of consolidated obligations (debt securities) totaling approximately $1.37 billion across five tranches with varying maturities and rate structures. While Item 2.03 typically signals covenant_breach or direct financial obligations of concern, this filing discloses routine debt issuances by a Federal Home Loan Bank in the ordinary course of business—a material but recurring funding activity. The disclosure emphasizes joint and several liability across all FHLBanks and provides detailed terms in Schedule A, but does not indicate a triggering event, breach, or acceleration of obligations that would warrant covenant_breach classification.
View raw filing on EDGAR →This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) totaling approximately $5.555 billion across six separate debt securities issued in June 2026. While Item 2.03 is the designated item for debt creation, the taxonomy lacks a specific "debt_issuance" category; the event is material to investors as it represents significant new financial obligations and capital market activity, but does not fit cleanly into the provided event types (covenant_breach applies to violations, not new issuances). This is classified as other_material rather than covenant_breach, which is reserved for triggering events that accelerate obligations.
View raw filing on EDGAR →The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds totaling approximately $130 million across three separate issuances with maturities ranging from one to two years. While Item 2.03 is titled "Creation of a Direct Financial Obligation," the disclosure is routine debt issuance reporting by a government-sponsored enterprise (FHLB) rather than a triggering covenant breach or material financial stress event. The bonds are joint and several obligations of all FHLBanks and are not government-guaranteed, making this a material financial obligation that would affect investor assessment, but it does not fit the specific "covenant_breach" category which implies acceleration or distress.
View raw filing on EDGAR →This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds totaling $70 million ($50M + $20M par amounts) by the Federal Home Loan Bank of Dallas. While the filing itself emphasizes that the Bank "has not made a judgment as to the materiality of these consolidated obligation bonds," the issuance of debt securities is a material financial obligation that would affect a reasonable investor's assessment of the registrant's capital structure and leverage. However, this does not fit neatly into the more specific event categories (e.g., it is not a covenant breach, dilutive issuance, or M&A activity), making "other_material" the most appropriate classification for routine debt issuance disclosure under Item 2.03.
View raw filing on EDGAR →FNF held its Annual Meeting of Stockholders on June 11, 2026, with shareholders voting on four proposals: election of four Class III directors, approval of amended articles to implement annual director elections (eliminating the classified board structure over three years with full annual elections beginning at the 2029 Annual Meeting), advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →Zach Sawtelle was appointed Chief Operating Officer effective June 10, 2026, and designated Chief Executive Officer effective January 1, 2027, succeeding retiring CEO Elias J. Sabo. This executive succession is material to investors' assessment of the company's leadership and strategic direction.
View raw filing on EDGAR →Veracyte held its Annual Meeting of stockholders and disclosed complete voting results on four proposals: election of nine directors, ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2023 Equity Incentive Plan increasing the share reserve by 3,500,000 shares. All proposals passed.
View raw filing on EDGAR →NXP held its 2026 Annual General Meeting on June 10, 2026, with shareholders voting on 11 resolutions including adoption of annual accounts, director re-appointments, board authorizations, auditor re-appointment, and executive compensation approvals. Detailed vote tallies (For/Against/Abstain/Broker Non-Votes) for each resolution were disclosed.
View raw filing on EDGAR →The Board approved an interim dividend of $1.014 per ordinary share payable in July 2026, representing a direct return of capital to shareholders.
View raw filing on EDGAR →The Board adopted amendments to the Company's Bylaws that materially reduce the quorum requirement from a majority to one-third of voting power and change the voting standard for non-director matters from a majority of shares present to a majority of votes cast. These governance changes lower the threshold for stockholder action and could affect the ease with which future proposals pass, making them material to investor assessment of corporate control dynamics, though they do not fit the more specific event categories in the taxonomy.
View raw filing on EDGAR →Shareholders voted on matters at the Annual Meeting held on June 10, 2026, including the election of five directors. The filing reports detailed vote tallies (for/withheld) for each director nominee.
View raw filing on EDGAR →The Board authorized a share repurchase program for up to 300,000 shares on June 10, 2026. The authorization signals management confidence in the company's valuation and reflects capital allocation decisions, though specific timing and pricing details were not disclosed.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder voting results from the Annual Meeting of Shareholders held on June 10, 2026. The filing reports the outcomes of three proposals: election of two directors (Scott Montross and John Paschal), an advisory vote on named executive officer compensation, and ratification of Baker Tilly US, LLP as independent auditors. The detailed vote tallies (For, Against, Abstain, Broker Non-votes) for each proposal are the hallmark of shareholder_vote_results disclosures.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of Genie Energy Ltd.'s Annual Meeting of Stockholders held on June 10, 2026, including the election of five Board of Directors nominees (Howard S. Jonas, Irwin Katsof, Joyce Mason, W. Wesley Perry, and Alan B. Rosenthal) and approval of an amendment to the 2021 Stock Option and Incentive Plan increasing available shares by 70,000. Board elections and equity plan amendments are material governance matters affecting investor interests.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on June 10, 2026, covering three proposals: election of Class B directors, advisory vote on executive compensation, and ratification of the independent auditor. The filing presents final voting tallies for each proposal, which is the core content of Item 5.07 and constitutes a material event affecting investor understanding of corporate governance outcomes.
View raw filing on EDGAR →The filing explicitly discloses financial results for the fourth quarter and fiscal year ended March 31, 2026 via a press release furnished as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides the company's periodic financial performance.
View raw filing on EDGAR →This Item 5.07 filing discloses the final results of Planet 13's 2026 annual shareholder meeting held on June 10, 2026, including voting outcomes on three proposals: election of seven directors, approval of an amendment to the 2023 Equity Incentive Plan increasing authorized shares from 32 million to 52 million, and ratification of Davidson & Company LLP as independent auditor. The detailed vote tallies for each director and proposal are material to investors assessing governance and capital structure decisions.
View raw filing on EDGAR →The filing discloses both a director resignation (Irwin Katsof) and a director appointment (William Conkling). While both events are present, the substantive focus and detail center on the appointment of Conkling, including his extensive background in pharmaceutical commercialization, his independence determination, and his committee assignments (Audit Committee Chair and Financial Expert). The resignation is noted as non-contentious and receives minimal disclosure. Director appointments are material to investors assessing board composition and governance.
View raw filing on EDGAR →The filing discloses commencement of legal proceedings by Regenerex Pharma against its former Chief Financial Officer, Kenneth W. Perry, seeking recovery of funds and other amounts allegedly owed, plus injunctive relief and damages. While filed under Item 5.02 (executive departures/appointments), the substantive disclosure centers on material litigation initiated by the company against a former executive officer, making this a material litigation event. The involvement of a CFO and allegations of misconduct during tenure would affect a reasonable investor's assessment of the company's governance and financial controls.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Sensata Technologies' Annual General Meeting of Shareholders held on June 9, 2026. The filing presents detailed voting results across 14 shareholder proposals, including director elections, executive compensation approval, auditor ratification, equity plan amendments, and share repurchase authorizations. All proposals passed with substantial majorities, making this a material disclosure of shareholder governance outcomes.
View raw filing on EDGAR →The filing discloses multiple executive appointments on June 9, 2026: Zhao Ling as CEO, Yang Fuzhu as Chairman, Zhang Wenmin as CFO, and four independent directors. While two departures also occurred (Chen Yuanhang as CEO and Wei Zurui as CFO/director), the dominant narrative and bulk of disclosure focuses on the new appointments with detailed biographical information for each appointee. This is a material leadership transition affecting the company's governance structure.
View raw filing on EDGAR →The filing discloses completion of a 1-for-5 reverse stock split effective June 11, 2026, reducing issued shares from approximately 367.7 million to 73.9 million and authorized shares from 5 billion to 1 billion. While reverse splits are routine capital structure adjustments, this one is material to investors as it affects share count, trading symbols, and CUSIP numbers. The event does not fit neatly into the specific taxonomy categories (not an earnings release, executive change, M&A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, or litigation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →The filing discloses a press release announcing 30-day results from the CGUARDIANS II clinical trial of the CGuard Prime 80 cm implant for TCAR procedures. This is a clinical trial result disclosure under Item 7.01 (Regulation FD Disclosure). While clinical trial results can be material to investors in medical device companies, this does not fit neatly into the standard taxonomy categories (not an earnings release, not a restatement, not litigation, etc.), making "other_material" the most appropriate classification.
View raw filing on EDGAR →The filing discloses a material restructuring of the Company's debt obligations under Item 2.03 (Creation of a Direct Financial Obligation). Nakamoto Inc. executed a Restructured Loan Term Sheet with Kraken on June 5, 2026, for 210,000,000 USDT secured by 4,405 Bitcoin, followed by a Partial Repayment of $45 million and a subsequent June Term Sheet for 165,000,000 USDT. While Item 2.03 typically signals covenant_breach or debt restructuring, the magnitude and complexity of this multi-tranche loan restructuring—involving collateral maintenance thresholds, liquidation triggers, and material asset pledges—resembles a material financing transaction. However, the core event is the creation of a direct financial obligation (debt restructuring) rather than an acquisition or change of control, making this ambiguous between covenant_breach, ma_activity, and other_material.
View raw filing on EDGAR →The filing discloses entry into a material supply agreement (Item 1.01) between TechForce Robotics (a wholly-owned subsidiary) and Jiun Jiang Enterprise for manufacturing robotic systems. While this is a supply/manufacturing agreement rather than a traditional M&A transaction, the three-year initial term with auto-renewal, IP licensing framework, and strategic manufacturing partnership suggest materiality. However, the lack of financial terms, deal value, or strategic context makes it difficult to assess whether this rises to the level of a traditional "material acquisition" or is better classified as a significant operational/commercial arrangement outside the standard taxonomy.
View raw filing on EDGAR →The filing's principal disclosure under Item 5.02 is an Amended and Restated Compensation Agreement with CEO Kevin O'Donnell, effective June 5, 2026. The agreement specifies a $550,000 annual base salary, a one-time $875,000 cash bonus, elimination of future annual bonus opportunities, and detailed severance and termination provisions. This is a material compensatory arrangement modification for a named executive officer that would affect investor assessment of executive pay and retention incentives.
View raw filing on EDGAR →The filing discloses results of the 2026 Annual Meeting of Stockholders held on June 11, 2026, under Item 5.07. Three proposals were voted upon: (1) election of Lucille Salhany as a Class III director, (2) advisory approval of executive compensation for fiscal year 2025, and (3) ratification of WithumSmith+Brown, PC as independent auditors for 2026. All three proposals passed with clear majorities. This is a standard shareholder vote results disclosure that is material to investors as it reflects governance decisions and auditor appointment.
View raw filing on EDGAR →Eric Kash resigned as Executive Vice President and Board member effective June 5, 2026. While the filing also discloses severance terms ($125,000 in installments, vested stock options, and accrued vacation), the principal disclosed action is the departure itself. The resignation was not due to disagreement, and the severance arrangement is ancillary to the departure event. This is material as executive departures affect investor assessment of management stability and governance.
View raw filing on EDGAR →The filing discloses results of Reed's, Inc.'s 2026 annual meeting of stockholders held on June 10, 2026, including voting outcomes on director elections, auditor ratification, approval of the 2026 Equity Incentive Plan, and advisory votes on executive compensation. Item 5.07 explicitly presents vote tallies (for, against, abstentions, broker non-votes) for each matter, which is the core disclosure requirement for shareholder vote results. While the filing also addresses executive compensation plan approval under Item 5.02(e), the primary substantive disclosure is the shareholder voting results themselves.
View raw filing on EDGAR →AIM ImmunoTech entered into a securities purchase agreement on June 9, 2026, to issue 2,554,119 registered shares at $0.5189 per share (approximately $1.3 million gross proceeds) and concurrently issued 771,503 unregistered shares plus pre-funded warrants and Class J warrants in a private placement. The filing explicitly discloses unregistered equity issuances under Item 3.02, with warrants exercisable for up to 12 million additional shares, representing substantial dilution to existing shareholders and a material capital raise typical of small-cap equity financings.
View raw filing on EDGAR →Item 5.07 discloses the results of Omega Flex's Annual Meeting of Shareholders held on June 10, 2026, with voting results for the election of three Class 3 directors (James M. Dubin, Kevin R. Hoben, and Dean W. Rivest). The filing's primary substantive disclosure is the shareholder vote outcome, which is material to investors as it confirms board composition and governance continuity.
View raw filing on EDGAR →The filing discloses results of an extraordinary general meeting held on June 11, 2026, where shareholders voted on and approved an amendment to extend the business combination deadline from June 14, 2026 to December 31, 2026. The vote tabulation shows 2,723,387 votes for, 4,376 against, and 17 abstentions, with 2,727,780 shares represented constituting a quorum. This is a classic Item 5.07 shareholder vote result disclosure, material to investors as it directly affects the timeline for the company's proposed business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.
View raw filing on EDGAR →The filing discloses a one-for-ten reverse stock split of Shuttle Pharmaceuticals' common stock, effective June 11, 2026, authorized by stockholders at the May 21, 2026 annual meeting and implemented by board action on June 1, 2026. While reverse stock splits are typically administrative in nature, this event is material to investors as it affects share count, exercise prices of warrants and convertible securities, and trading mechanics on Nasdaq. The event does not fit neatly into the specific taxonomy categories (it is not an earnings release, executive change, M&A activity, restatement, auditor change, going concern, impairment, shareholder vote results, delisting risk, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, or material litigation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →The filing discloses a material sale-leaseback transaction under Item 1.01 (Entry into a Material Definitive Agreement). On June 5, 2026, the Company's subsidiary sold approximately 9.5 acres of land underlying the Ford Amphitheater to O'Neil Roth Ford, LLC for $49.7 million in cash and a $19.88 million promissory note, with concurrent entry into a new 25-year ground lease at increased annual rent of $4.224 million. This constitutes a material disposition of a significant operating asset, with related financing and equity issuance (5 million warrants at $3.79/share), affecting the Company's capital structure and liquidity.
View raw filing on EDGAR →The 8-K discloses under Item 7.01 (Regulation FD Disclosure) that Laser Photonics issued a press release regarding "financial results and accomplishments achieved during the quarter ended March 31, 2026." The press release is furnished as Exhibit 99.1. This is a standard earnings release disclosure for Q1 2026 results, which is material to investors assessing the company's financial performance.
View raw filing on EDGAR →The filing discloses Item 5.07 results from U.S. GoldMining's June 11, 2026 annual meeting of stockholders, including voting results for the election of six directors (Alastair Still, Garnet Dawson, Ross Sherlock, Lisa Wade, Laura Schmidt, and Aleksandra Bukacheva) and ratification of Deloitte LLP as independent auditor. This is a standard shareholder vote results disclosure that materially informs investors of board composition and auditor approval.
View raw filing on EDGAR →The filing's primary substantive disclosure under Item 5.02 is the appointment of Jordan Zwick to the Board of Directors on June 10, 2026, expanding the Board from five to six directors. While the filing also covers shareholder vote results (Item 5.07) and equity plan amendments, the appointment of a new director with Audit Committee assignment is the most salient executive personnel action disclosed and would be material to investors assessing board composition and governance.
View raw filing on EDGAR →The filing discloses a private placement of 96,000,000 shares of common stock for $300,000 in cash pursuant to Subscription Agreements executed on June 6 and June 11, 2026, with institutional and accredited investors under Section 4(a)(2) and Rule 506(b) exemptions. This represents a highly dilutive unregistered equity issuance at a minimal valuation ($0.003125 per share), which is material to investors assessing the registrant's capital structure and shareholder value.
View raw filing on EDGAR →Arq, Inc. held its Annual Meeting of Stockholders and disclosed voting results on five proposals: election of six directors, advisory vote on executive compensation, ratification of auditor Baker Tilly US, LLP, approval of the 2026 Omnibus Incentive Plan, and approval of the Ninth Amendment to the Tax Asset Protection Plan. All proposals passed with substantial majorities.
View raw filing on EDGAR →Marqeta held its 2026 Annual Meeting of Shareholders on June 10, 2026, with final voting results disclosed for five proposals: election of four Class II directors, ratification of KPMG LLP as auditor, approval of a 1-for-4 reverse stock split, officer exculpation amendment, and advisory vote on named executive officer compensation.
View raw filing on EDGAR →Shareholders approved and the Board authorized a 1-for-4 reverse stock split with a corresponding reduction in authorized shares, a structural corporate action affecting the company's share structure and capitalization.
View raw filing on EDGAR →